Orchid Pharma Limited

Net profit volatility: swung from +₹30.6 Cr to -₹12.61 Cr across recent quarters, raising questions about operational control and business stability.

Valuation disconnect: PE of 260.39 and ROE of 1.61% suggest the stock is priced for significant improvement; verify what operational or market catalyst is expected.

Margin instability: operating margins ranged from -0.76% to +12.2% quarter-to-quarter; verify whether this reflects product mix, cost control, pricing, or one-time items.

No shareholder returns: no dividends since 2012, and current low profitability makes future payouts uncertain.

Revenue grew 37% over three quarters from ₹173 Cr (Jun 2025) to ₹238 Cr (Mar 2026).

Mar 2026 net profit of ₹30.6 Cr and operating margin of 12.2% were highest in recent quarters; verify if this level is repeatable and what drove the improvement.

Low leverage (D/E 0.28) provides balance-sheet capacity for reinvestment or growth; verify management's capital allocation strategy.

Pharma sector in India has structural growth drivers; verify Orchid's competitive position, product portfolio, and addressable market opportunities.